Endometriosis Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight
' Endometriosis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Endometriosis Market.
The Endometriosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Endometriosis Pipeline Report:
Companies across the globe are diligently working toward developing novel Endometriosis treatment therapies with a considerable amount of success over the years.
Endometriosis companies working in the treatment market are Organon, Ironwood Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, AbbVie/Neurocrine Biosciences, ObsEva/Kissei Pharmaceuticals, SWK/Enteris BioPharma, Bayer/Hope Medicine, Tiumbio, and others, are developing therapies for the Endometriosis treatment
Emerging Endometriosis therapies in the different phases of clinical trials are- FOR 6219, IW-3300, MT-2990, ORIAHNN (elagolix/estradiol/norethindrone acetate), Linzagolix (OBE2109), OVAREST (leuprorelin oral), HMI-115, TU2670 (NCE-403), OG-6219, and others are expected to have a significant impact on the Endometriosis market in the coming years.
In July 2025, A drug candidate once described by Organon as its 'biggest potential opportunity' failed in a Phase 2 clinical trial, leading the company to discontinue its development for Endometriosis. Organon, a women's health-focused company, acquired the candidate OG-6219 through its $75 million acquisition of Forendo Pharma in 2021, shortly after spinning off from Merck & Co. The company launched a Phase 2 trial in 2022, enrolling 354 premenopausal women suffering from moderate to severe Endometriosis-related pain. Participants were randomized to receive one of three doses of OG-6219 or a placebo. Organon had hoped the drug would alleviate pain by inhibiting a hormone involved in uterine tissue growth and inflammation, but the trial failed to meet expectations.
In March 2025, The first long-term daily oral treatment for Endometriosis has been recommended for routine use on the NHS in England. In its final draft guidance, the National Institute for Health and Care Excellence (NICE) advised that relugolix-estradiol-norethisterone, also known as relugolix combination therapy (relugolix CT), should be offered to adults of reproductive age whose Endometriosis symptoms persist despite previous medical or surgical treatments. This marks the first time a daily pill of this kind has been approved for long-term Endometriosis management by the NHS, with around 1,000 women expected to benefit each year.
In October 2024, Lisata Therapeutics, Inc. entered into a sponsored research collaboration with the University of Cincinnati to explore its innovative cyclic peptide candidate, certepetide, in combination with bevacizumab (a VEGF inhibitor). The study will utilize a preclinical animal model to evaluate the potential of this combination therapy for treating Endometriosis.
In October 2024, Hope Medicine Inc. reported positive findings from an interim analysis of its global Phase II trial, titled "A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of HMI-115 in Women with Moderate to Severe Endometriosis-Associated Pain Over a 12-Week Treatment Period." HMI-115, a monoclonal antibody that inhibits the prolactin receptor, represents a first-in-class therapy for Endometriosis. Notably, the National Medical Products Administration (NMPA) in China has granted HMI-115 Breakthrough Therapy Designation.
In May 2024, Neurocrine Biosciences, Inc. has commenced its Phase I first-in-human clinical trial to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of the investigational drug NBI-1117567 in healthy adults. NBI-1117567 is an experimental oral selective muscarinic agonist, with a preference for M1 over M4 receptors, being developed as a potential treatment for neurological and neuropsychiatric disorders
In May 2024, TiumBio Co., Ltd., a company dedicated to developing innovative treatments for rare and incurable diseases, reported positive topline results from its Phase 2a clinical trial evaluating Merigolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, for the treatment of moderate to severe Endometriosis-associated pain.
In April 2024, By the end of this year, Gynica, an Israeli company, plans to administer the first dose in a Phase I trial for its cannabinoid-based therapies, IntraVagS301 and IntraVagS302, designed for Endometriosis. This trial aims to assess the safety, toxicity, and pharmacokinetics of these drugs, which utilize microencapsulation technology
Endometriosis Overview
Endometriosis is a chronic medical condition where tissue similar to the lining of the uterus (endometrium) grows outside the uterus, often on the ovaries, fallopian tubes, and other pelvic organs. This tissue responds to hormonal changes and can cause pain, inflammation, scar tissue, and fertility issues. Common symptoms include severe menstrual cramps and pelvic pain.
Emerging Endometriosis Drugs Under Different Phases of Clinical Development Include:
Endometriosis Route of Administration
Endometriosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Inhalation
Inhalation/Intravenous/Oral
Intranasal
Intravenous
Intravenous/ Subcutaneous
NA
Oral
Oral/intranasal/subcutaneous
Parenteral
Subcutaneous
Endometriosis Molecule Type
Endometriosis Products have been categorized under various Molecule types, such as
Antibody
Antisense oligonucleotides
Immunotherapy
Monoclonal antibody
Peptides
Protein
Recombinant protein
Small molecule
Stem Cell
Vaccine
Endometriosis Pipeline Therapeutics Assessment
Endometriosis Assessment by Product Type
Endometriosis By Stage and Product Type
Endometriosis Assessment by Route of Administration
Endometriosis By Stage and Route of Administration
Endometriosis Assessment by Molecule Type
Endometriosis by Stage and Molecule Type
DelveInsight's Endometriosis Report covers around 20+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Some of the key companies in the Endometriosis Therapeutics Market include:
Key companies developing therapies for Endometriosis are - AbbVie, Neurocrine Biosciences, Kissei Pharmaceuticals, SWK, Enteris BioPharma, Bayer, Hope Medicine, Tiumbio, Organon, Ferring Pharmaceuticals, ObsEva SA, Myovant Sciences, Hope Medicine (Nanjing) Co., Ltd, TiumBio Co., Ltd., Mitsubishi Tanabe Pharma, and others.
Endometriosis Pipeline Analysis:
The Endometriosis pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Endometriosis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Endometriosis Treatment.
Endometriosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Endometriosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Endometriosis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Endometriosis Pipeline Market Drivers
The development of drug delivery systems represents a new approach in pain treatment among Endometriosis patients, extensive research on Non-steroidal anti-inflammatory drugs are some of the important factors that are fueling the Endometriosis Market.
Endometriosis Pipeline Market Barriers
However, less robust pipeline, high cost of treatment procedures and other factors are creating obstacles in the Endometriosis Market growth.
Scope of Endometriosis Pipeline Drug Insight
Coverage: Global
Key Endometriosis Companies: Organon, Ironwood Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, AbbVie/Neurocrine Biosciences, ObsEva/Kissei Pharmaceuticals, SWK/Enteris BioPharma, Bayer/Hope Medicine, Tiumbio, and others
Key Endometriosis Therapies: FOR 6219, IW-3300, MT-2990, ORIAHNN (elagolix/estradiol/norethindrone acetate), Linzagolix (OBE2109), OVAREST (leuprorelin oral), HMI-115, TU2670 (NCE-403), OG-6219, and others
Endometriosis Therapeutic Assessment: Endometriosis current marketed and Endometriosis emerging therapies
Endometriosis Market Dynamics: Endometriosis market drivers and Endometriosis market barriers
Table of Contents
1. Endometriosis Report Introduction
2. Endometriosis Executive Summary
3. Endometriosis Overview
4. Endometriosis- Analytical Perspective In-depth Commercial Assessment
5. Endometriosis Pipeline Therapeutics
6. Endometriosis Late Stage Products (Phase II/III)
7. Endometriosis Mid Stage Products (Phase II)
8. Endometriosis Early Stage Products (Phase I)
9. Endometriosis Preclinical Stage Products
10. Endometriosis Therapeutics Assessment
11. Endometriosis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Endometriosis Key Companies
14. Endometriosis Key Products
15. Endometriosis Unmet Needs
16 . Endometriosis Market Drivers and Barriers
17. Endometriosis Future Perspectives and Conclusion
18. Endometriosis Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Pediatric Obesity Market Expected to Experience Major Growth by 2034, According to DelveInsight
DelveInsight's 'Pediatric Obesity Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Pediatric Obesity, historical and forecasted epidemiology as well as the Pediatric Obesity market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. Some of the key facts of the Pediatric Obesity Market Report: The Pediatric Obesity market size is anticipated to grow with a significant CAGR during the study period (2020-2034) In September 2024, Novo Nordisk highlighted the effectiveness of its obesity treatment, Saxenda (liraglutide), in children under 12 through positive Phase III trial results. Participants receiving Saxenda experienced an average reduction of 5.8% in body mass index (BMI), whereas the placebo group saw a decrease of only 1.6%. The Phase III trial findings were presented at the European Association for the Study of Diabetes (EASD) conference in Spain. In 2023, around 8 million children aged 5 to 19 were affected by obesity across the 7MM. With ongoing lifestyle trends, this figure is anticipated to rise substantially in the coming years. Research indicates that the prevalence of overweight, including obesity, among children and adolescents aged 5–19 has surged from 8% in 1990 to 20% in 2022. This increase has been observed in both genders, with 19% of girls and 21% of boys classified as overweight in 2022. Among the EU4 and the UK, Germany recorded the highest prevalence of childhood obesity cases, while Spain had the lowest. Rhythm Pharmaceuticals intends to file a supplemental New Drug Application (sNDA) with the US FDA in Q2 2024 to extend IMCIVREE's label to include children aged 2 to 6 years Key Pediatric Obesity Companies: Novo Nordisk, Eli Lilly and Company, VIVUS LLC, Novartis, Rhythm Pharma, Jack Yanovski, and others Key Pediatric Obesity Therapies: WEGOVY (semaglutide), SAXENDA (liraglutide), Tirzepatide, VI-0521, Sandostatin LAR, Setmelanotide, Orlistat, and others The Pediatric Obesity market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Pediatric Obesity pipeline products will significantly revolutionize the Pediatric Obesity market dynamics. Pediatric Obesity Overview Pediatric obesity refers to the condition of having excess body fat in children and adolescents. It is a complex medical condition characterized by an abnormal or excessive accumulation of fat that may negatively affect a child's health and well-being. Pediatric Obesity Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Pediatric Obesity Epidemiology Segmentation: The Pediatric Obesity market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Download the report to understand which factors are driving Pediatric Obesity epidemiology trends @ Pediatric Obesity Epidemiology Forecast Pediatric Obesity Drugs Uptake and Pipeline Development Activities The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Pediatric Obesity market or expected to get launched during the study period. The analysis covers Pediatric Obesity market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Pediatric Obesity Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. Pediatric Obesity Therapies and Key Companies Scope of the Pediatric Obesity Market Report Study Period: 2020–2034 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Pediatric Obesity Companies: Novo Nordisk, Eli Lilly and Company, VIVUS LLC, Novartis, Rhythm Pharmaceuticals, Jack Yanovski, and others Key Pediatric Obesity Therapies: WEGOVY (semaglutide), SAXENDA (liraglutide), Tirzepatide, VI-0521, Sandostatin LAR, Setmelanotide, Orlistat, and others Pediatric Obesity Therapeutic Assessment: Pediatric Obesity current marketed and Pediatric Obesity emerging therapies Pediatric Obesity Market Dynamics: Pediatric Obesity market drivers and Pediatric Obesity market barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Pediatric Obesity Unmet Needs, KOL's views, Analyst's views, Pediatric Obesity Market Access and Reimbursement Table of Contents 1. Pediatric Obesity Market Report Introduction 2. Executive Summary for Pediatric Obesity 3. SWOT analysis of Pediatric Obesity 4. Pediatric Obesity Patient Share (%) Overview at a Glance 5. Pediatric Obesity Market Overview at a Glance 6. Pediatric Obesity Disease Background and Overview 7. Pediatric Obesity Epidemiology and Patient Population 8. Country-Specific Patient Population of Pediatric Obesity 9. Pediatric Obesity Current Treatment and Medical Practices 10. Pediatric Obesity Unmet Needs 11. Pediatric Obesity Emerging Therapies 12. Pediatric Obesity Market Outlook 13. Country-Wise Pediatric Obesity Market Analysis (2020–2034) 14. Pediatric Obesity Market Access and Reimbursement of Therapies 15. Pediatric Obesity Market Drivers 16. Pediatric Obesity Market Barriers 17. Pediatric Obesity Appendix 18. Pediatric Obesity Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Gaurav Bora Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
a day ago
- Globe and Mail
AbbVie and Genmab's Promising Phase 3 Study for DLBCL Treatment
Abbvie ((ABBV)), Genmab (Otc) ((GMAB)), Abbvie (($CC: announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. AbbVie and Genmab are conducting a Phase 3 clinical study to evaluate the safety and efficacy of epcoritamab plus lenalidomide compared to rituximab plus gemcitabine and oxaliplatin in treating relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL). This study is significant as it explores new treatment options for this aggressive form of cancer, potentially improving patient outcomes. The study involves three treatment arms: one receiving subcutaneous injections of epcoritamab plus oral lenalidomide, another receiving intravenous rituximab plus gemcitabine and oxaliplatin, and a third receiving only epcoritamab. The goal is to determine which treatment is most effective in managing DLBCL. This randomized, open-label study follows a parallel intervention model with no masking. Its primary purpose is treatment, aiming to enroll around 360 participants across 165 global sites. The study began on August 13, 2024, with an estimated completion date yet to be announced. The last update was submitted on August 4, 2025, indicating ongoing progress. For investors, this study could impact AbbVie and Genmab's stock performance, especially if the results show promising outcomes. The competitive landscape in oncology treatments is fierce, and successful trials can lead to significant market advantages. The study is ongoing, with further details available on the ClinicalTrials portal.
Globe and Mail
a day ago
- Globe and Mail
Dendreon Pharma, Candel Therapeutics, GlaxoSmithKline, Merck, Aduro Biotech, Astrazeneca Plc, Dendreon
The Key Cancer Vaccines Companies in the market include - Dendreon Pharma, Candel Therapeutics, GlaxoSmithKline, Merck, Aduro Biotech, Astrazeneca Plc, Dendreon, Astellas Pharma Inc, Sanofi, , Sanpower Group and CSL Ltd., Northwest Biotherapeutics, IO Biotech, Immunomic Therapeutics, Evaxion Biotech, Candel Therapeutics, Aston Sci, Evaxion Biotech, and others. DelveInsight's 'Cancer Vaccines Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Cancer Vaccines, historical and forecasted epidemiology as well as the Cancer Vaccines market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. Some of the key facts of the Cancer Vaccines Market Report: The Cancer Vaccines market size is anticipated to grow with a significant CAGR during the study period (2020-2034) In March 2025, Everest Medicines administered the first dose of EVM16, its personalized mRNA cancer vaccine, to a participant in the first-in-human (FIH) trial, EVM16CX01. In February 2025, In a Phase I investigator-led trial, all nine patients who received a personalized kidney cancer vaccine developed anti-cancer immune responses after undergoing tumor removal surgery. Researchers at the Dana-Farber Cancer Institute in the U.S. administered the NeoVax personalized cancer vaccine to patients with stage III or IV clear cell renal cell carcinoma (ccRCC) following their surgeries. In August 2024, BioNTech launched global clinical trials for BNT116, an mRNA vaccine being developed as a potential treatment for non-small cell lung cancer (NSCLC). The vaccine utilizes the same mRNA technology that played a crucial role in the development of Covid-19 vaccines. In February 2024, A cancer vaccine trial initiated by Moderna commenced in the UK, with researchers optimistic about ushering in a new era of treatments. In 2023, the estimated number of incident cases of non-small cell lung cancer (NSCLC) in the US was approximately 200,000. Uveal melanoma impacts approximately 500 to 600 individuals annually in the UK. The cancer vaccines market features a robust and expanding pipeline with candidates such as IO102-IO103 (IO Biotech), CAN-2409 (Candel Therapeutics), mRNA-4157 (V940) combined with KEYTRUDA (Merck and Moderna), PDClung01 (PDCline Pharma/LG Chem), and LB-LR1109 (LG Chem and AVEO Oncology). These vaccines target a variety of cancers, including non-small cell lung cancer (NSCLC), colorectal cancer, glioblastoma, melanoma, breast cancer, and more. Key Cancer Vaccines Companies: Dendreon Pharma, Candel Therapeutics, GlaxoSmithKline, Merck, Aduro Biotech, Astrazeneca Plc, Dendreon, Astellas Pharma Inc, Sanofi, , Sanpower Group and CSL Ltd., Northwest Biotherapeutics, IO Biotech, Immunomic Therapeutics, Evaxion Biotech, Candel Therapeutics, Aston Sci, Evaxion Biotech, and others Key Cancer Vaccines Therapies: DCVax-L, IO102-IO103, ITI-1000, EVX-01, CAN-2409, AST-301, EVX-02, and others Several vaccine constructions have been tested for anticancer therapy. In each case, these vaccines are designed to present tumor-associated peptides integrated with MHC molecules to cognate receptors on B or T lymphocytes and stimulate their activation, maturation, and proliferation The Cancer Vaccines market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cancer Vaccines pipeline products will significantly revolutionize the Cancer Vaccines market dynamics. Cancer Vaccines Overview Cancer vaccines are a type of immunotherapy designed to stimulate the body's immune system to recognize and attack cancer cells. Unlike traditional vaccines, which prevent infectious diseases by priming the immune system to recognize and fight off specific pathogens (such as viruses or bacteria), cancer vaccines are used to treat existing cancer or to prevent cancer recurrence. Cancer Vaccines Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Cancer Vaccines Epidemiology Segmentation: The Cancer Vaccines market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Cancer Vaccines Drugs Uptake and Pipeline Development Activities The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cancer Vaccines market or expected to get launched during the study period. The analysis covers Cancer Vaccines market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Cancer Vaccines Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. Cancer Vaccines Therapies and Key Companies Cancer Vaccines Market Strengths Advancements in computational and bioinformatics platforms and several other R&D practices enable the development of cancer neoantigen vaccination strategies Neoantigen-based Personalized Cancer Therapeutic Vaccines like Vigil and Tedopi along with few others can stimulate immune responses to checkpoint inhibitors even in patients that have previously failed conventional treatment regimes, thereby, addressing potential unmet needs of the market Cancer Vaccines Market Opportunities Rising incidence of cancer will provide a larger window of opportunity for these novel vaccines Recurrence is very common in cancers even after proper treatment. This opens up new window for Neoantigen-based Personalized Cancer Therapeutic Vaccines to dominate the treatment regime Scope of the Cancer Vaccines Market Report Table of Contents 1. Cancer Vaccines Market Report Introduction 2. Executive Summary for Cancer Vaccines 3. SWOT analysis of Cancer Vaccines 4. Cancer Vaccines Patient Share (%) Overview at a Glance 5. Cancer Vaccines Market Overview at a Glance 6. Cancer Vaccines Disease Background and Overview 7. Cancer Vaccines Epidemiology and Patient Population 8. Country-Specific Patient Population of Cancer Vaccines 9. Cancer Vaccines Current Treatment and Medical Practices 10. Cancer Vaccines Unmet Needs 11. Cancer Vaccines Emerging Therapies 12. Cancer Vaccines Market Outlook 13. Country-Wise Cancer Vaccines Market Analysis (2020–2034) 14. Cancer Vaccines Market Access and Reimbursement of Therapies 15. Cancer Vaccines Market Drivers 16. Cancer Vaccines Market Barriers 17. Cancer Vaccines Appendix 18. Cancer Vaccines Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Gaurav Bora Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
